Krystal Biotech, Inc. $KRYS Shares Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 350.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 9,000 shares of the company’s stock after acquiring an additional 7,000 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Krystal Biotech were worth $2,219,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Avoro Capital Advisors LLC grew its stake in Krystal Biotech by 4.4% in the 3rd quarter. Avoro Capital Advisors LLC now owns 2,777,777 shares of the company’s stock valued at $490,361,000 after acquiring an additional 117,777 shares during the period. State Street Corp grew its stake in Krystal Biotech by 10.5% in the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock valued at $186,306,000 after acquiring an additional 128,639 shares during the period. Soleus Capital Management L.P. grew its stake in Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after acquiring an additional 481,200 shares during the period. Dimensional Fund Advisors LP grew its stake in Krystal Biotech by 5.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 533,964 shares of the company’s stock valued at $94,261,000 after acquiring an additional 28,075 shares during the period. Finally, First Trust Advisors LP grew its stake in Krystal Biotech by 11.7% in the 3rd quarter. First Trust Advisors LP now owns 248,392 shares of the company’s stock valued at $43,849,000 after acquiring an additional 26,022 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $267.60, for a total transaction of $200,700.00. Following the sale, the chief accounting officer owned 22,366 shares of the company’s stock, valued at $5,985,141.60. The trade was a 3.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the transaction, the insider owned 1,403,155 shares in the company, valued at approximately $369,324,427.55. This represents a 1.75% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 116,664 shares of company stock worth $31,136,828. Company insiders own 13.10% of the company’s stock.

Krystal Biotech Stock Down 3.2%

Shares of KRYS opened at $306.29 on Friday. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $319.48. The firm’s fifty day moving average is $268.10 and its two-hundred day moving average is $253.29. The stock has a market cap of $9.03 billion, a PE ratio of 40.95 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The company had revenue of $116.36 million for the quarter, compared to analysts’ expectations of $112.11 million. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 7.98 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Zacks Research cut shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Citigroup lifted their price target on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. The Goldman Sachs Group lifted their price target on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $310.00 price target on shares of Krystal Biotech in a research note on Monday, May 4th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.